

AmpliPhi Biosciences Corp  
Form POS EX  
October 12, 2018

**As filed with the Securities and Exchange Commission on October 11, 2018**

**Registration No. 333-226959**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**POST EFFECTIVE AMENDMENT NO. 1  
TO  
FORM S-1**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**AmpliPhi Biosciences Corporation**

**(Exact Name of Registrant as Specified in Its Charter)**



San Diego, California 92121

(858) 550-6000

**Approximate date of commencement of proposed sale to the public:**

As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the "Securities Act"), check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  (File No. 333-226959)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer

Non-accelerated filer  Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B)

of the Securities Act.

**This post-effective amendment shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(d) under the Securities Act of 1933, as amended.**

**EXPLANATORY NOTE**

This Post-Effective Amendment No. 1 (this “Amendment”) relates to the Registrant’s Registration Statement on Form S-1 (File No. 333-226959), as amended, declared effective on October 11, 2018 by the Securities and Exchange Commission. The Registrant is filing this Amendment for the sole purpose of replacing Exhibit 5.1 to the Registration Statement. This Amendment does not modify any provision of Part I or Part II of the Registration Statement other than Item 16(a) of Part II as set forth below.

**PART II**

**INFORMATION NOT REQUIRED IN PROSPECTUS**

**Item 16. Exhibits and financial statement schedules.**

*(a) Exhibits.*

<b>Exhibit Number</b>	<b>Description of Document</b>
-----------------------	--------------------------------

<u>5.1</u>	<u>Opinion of Cooley LLP.</u>
<u>23.1</u>	<u>Consent of Cooley LLP. Reference is made to Exhibit 5.1.</u>
<u>24.1<sup>(a)</sup></u>	<u>Power of Attorney.</u>

(a) Included on the signature page of Registration Statement on Form S-1 (File No. 333-226959), filed with the Securities and Exchange Commission on August 21, 2018, and incorporated herein by reference.

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on the 11<sup>th</sup> day of October, 2018.

### **AMPLIPHI BIOSCIENCES CORPORATION**

By: /s/ Paul C. Grint, M.D.  
Paul C. Grint, M.D.

*Chief Executive Officer*

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

<b>Signature</b>	<b>Title</b>	<b>Date</b>
/s/ Paul C. Grint, M.D. Paul C. Grint, M.D.	Chief Executive Officer and Director <i>(Principal Executive Officer)</i>	October 11, 2018
/s/ Steve R. Martin Steve R. Martin	Chief Financial Officer <i>(Principal Financial and Accounting Officer)</i>	October 11, 2018
/s/ Jeremy Curnock Cook* Jeremy Curnock Cook	Chairman of the Board of Directors	October 11, 2018
/s/ Louis Drapeau* Louis Drapeau	Director	October 11, 2018
/s/ Wendy S. Johnson* Wendy S. Johnson	Director	October 11, 2018

Edgar Filing: AmpliPhi Biosciences Corp - Form POS EX

/s/ Michael S. Perry, Ph.D.\* Director  
Michael S. Perry, Ph.D.

October 11, 2018

/s/ Vijay B. Samant\* Director  
Vijay B. Samant

October 11, 2018

\*Pursuant to Power of Attorney

By: /s/ Paul C. Grint, M.D.  
Paul C. Grint, M.D.  
Attorney-in-Fact